Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC)

被引：11

作者：

McCarthy, Fiona ^{[1
]}

Roshani, Rozita ^{[1
]}

Steele, Jeremy ^{[2
]}

Hagemann, Thorsten ^{[1
]}

机构：

[1] Univ London, Ctr Canc & Inflammat, Barts Canc Inst, John Vane Sci Ctr, London EC1M 6BQ, England

[2] St Bartholomews Hosp, London, England

来源：

JOURNAL OF LEUKOCYTE BIOLOGY | 2013年 / 94卷 / 06期

关键词：

immunotherapeutic agents; malignancies; tumor; progression-free survival; CD8(+) T-CELLS; PROGNOSTIC-FACTOR; VACCINE; STAGE; MUC1; EXPRESSION; INFILTRATION; ANTIBODY; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1189/jlb.0313121

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Review of current immunotherapeutic approaches in the treatment of non-small cell lung cancer. NSCLC remains one of the most challenging malignancies to treat. Despite the introduction of innovative therapies over the last decade, the 5-year survival of NSCLC is still <20%. Clearly, novel, therapeutic approaches are required. Targeting the immune system to derive meaningful clinical benefit has proved successful in various malignancies in recent years. As a result, there is renewed focus on the use of immunotherapy in lung cancer. In this review, we provide an overview of current immune-modulatory approaches in the treatment of NSCLC.

引用

页码：1201 / 1206

页数：6

共 55 条

[1] Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer [J].

Al-Shibli, Khalid I. ;

Donnem, Tom ;

Al-Saad, Samer ;

Persson, Magnus ;

Bremnes, Roy M. ;

Busund, Lill-Tove .

CLINICAL CANCER RESEARCH, 2008, 14 (16) :5220-5227

[2] Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells [J].

Auffray, Cedric ;

Sieweke, Michael H. ;

Geissmann, Frederic .

ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :669-692

[3] Elevated CD14++CD16- Monocytes Predict Cardiovascular Events [J].

Berg, Katarina E. ;

Ljungcrantz, Irena ;

Andersson, Linda ;

Bryngelsson, Carl ;

Hedblad, Bo ;

Fredrikson, Gunilla N. ;

Nilsson, Jan ;

Bjorkbacka, Harry .

CIRCULATION-CARDIOVASCULAR GENETICS, 2012, 5 (01) :122-131

[4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[5]

BURCHELL J, 1987, CANCER RES, V47, P5476

[6] Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].

Butts, C ;

Murray, N ;

Maksymiuk, A ;

Goss, G ;

Marshall, E ;

Soulières, D ;

Cormier, Y ;

Ellis, P ;

Price, A ;

Sawhney, R ;

Davis, M ;

Mansi, J ;

Smith, C ;

Vergidis, D ;

Ellis, P ;

MacNeil, M ;

Palmer, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681

[7] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Crino, L. ;

Weder, W. ;

van Meerbeeck, J. ;

Felip, E. .

ANNALS OF ONCOLOGY, 2010, 21 :v103-v115

[8]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[9] Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment [J].

Fong, Lawrence ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5275-5283

[10] Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy [J].

Gonzalez, G ;

Crombet, T ;

Torres, F ;

Catala, M ;

Alfonso, L ;

Osorio, M ;

Neninger, E ;

Garcia, B ;

Mulet, A ;

Perez, R ;

Lage, R .

ANNALS OF ONCOLOGY, 2003, 14 (03) :461-466

← 1 2 3 4 5 6 →